Vaccines and Global Health: The Week in Review
22 October 2022 :: Issue 676
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
::
Journal Watch
**Milestones, Perspectives**

---

**Polio**

**Global leaders commit $US2.6 billion at World Health Summit to end polio**

**Press release**

BERLIN, 18 October 2022 – Today, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s (GPEI) **2022-2026 Strategy** to end polio at a pledging moment co-hosted by Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) at the World Health Summit in Berlin. The funding will support global efforts to overcome the final hurdles to polio eradication, vaccinate 370 million children annually over the next five years and continue disease surveillance across 50 countries...

“The new detections of polio this year in previously polio-free countries are a stark reminder that if we do not deliver our goal of ending polio everywhere, it may resurge globally,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “We are grateful for donors’ new and continued support for eradication, but there is further work to do to fully fund the 2022-2026 Strategy. We must remember the significant challenges we have overcome to get this far against polio, stay the course and finish the job once and for all.”

At a challenging time for countries around the world, governments and partners have stepped forward to demonstrate their collective resolve to eradicate the second human disease ever. In addition to existing pledges, new commitments to the 2022-2026 Strategy this fall include:

- Australia pledged AU$ 43.55 million
- France pledged EUR 50 million
- Germany pledged EUR 72 million
- Japan pledged US$ 11 million
- Republic of Korea pledged KRW 4.5 billion
- Luxembourg pledged EUR 1.7 million
- Malta pledged EUR 30 000
- Monaco pledged EUR 450 000
- Spain pledged EUR 100 000
- Turkey pledged US$ 20 000
- United States pledged US$ 114 million
- Bill & Melinda Gates Foundation pledged US$S 1.2 billion
- Bloomberg Philanthropies pledged US$ 50 million
- Islamic Food and Nutrition Council of America pledged US$ 1.8 million
- Latter-day Saint Charities pledged US$ 400 000
- Rotary International pledged US$ 150 million
- UNICEF pledged US$ 5 million

The pledging moment in Berlin marked the first major opportunity to pledge support toward the US$ 4.8 billion needed to fully implement the **2022-2026 Strategy**. If the Strategy is fully funded and eradication achieved, it is estimated that it would result in US$ 33.1 billion
in health cost savings this century compared to the price of controlling outbreaks. Further, continued support for GPEI will enable it to deliver additional health services and immunizations alongside polio vaccines to underserved communities...

::::::

::::::

**Cholera; Vaccine Supply**

**Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide**

19/10/2022 | Press release

Joint press release by the International Coordinating Group (ICG), an international group that manages and coordinates the provision of emergency vaccine supplies and antibiotics to countries during major disease outbreaks. The ICG is composed of members of IFRC, WHO, Médecins Sans Frontières, and UNICEF.

Geneva/New York, 19 October 2022 - A strained global supply of cholera vaccines has obliged the International Coordinating Group (ICG)—the body which manages emergency supplies of vaccines—to temporarily suspend the standard two-dose vaccination regimen in cholera outbreak response campaigns, using instead a single-dose approach.

The pivot in strategy will allow for the doses to be used in more countries, at a time of unprecedented rise in cholera outbreaks worldwide.

Since January this year, 29 countries have reported cholera cases, including Haiti, Malawi and Syria which are facing large outbreaks. In comparison, in the previous 5 years, fewer than 20 countries on average reported outbreaks. The global trend is moving towards more numerous, more widespread and more severe outbreaks, due to floods, droughts, conflict, population movements and other factors that limit access to clean water and raise the risk of cholera outbreaks.

The one-dose strategy has proven to be effective to respond to outbreaks, even though evidence on the exact duration of protection is limited, and protection appears to be much lower in children. With a two-dose regimen, when the second dose is administrated within 6 months of the first, immunity against infection lasts for 3 years.

The benefit of supplying one dose still outweighs no doses: although the temporary interruption of the two-dose strategy will lead to a reduction and shortening of immunity, this decision will allow more people to be vaccinated and provide them protection in the near term, should the global cholera situation continue deteriorating.

The current supply of cholera vaccines is extremely limited. Its use for emergency response is coordinated by the ICG which manages the global stockpile of oral cholera vaccines. Of the total 36 million doses forecast to be produced in 2022, 24 million have already been shipped for preventive (17%) and reactive (83%) campaigns and an additional 8 million doses were approved by the ICG for the second round for emergency vaccination in 4 countries, illustrating the dire shortage of the vaccine. As vaccine manufactures are producing at their maximum current capacity, there is no short-term
solution to increase production. The temporary suspension of the two-dose strategy will allow the remaining doses to be redirected for any needs for the rest of the year.

This is a short-term solution but to ease the problem in the longer term, urgent action is needed to increase global vaccine production. The ICG will continue to monitor the global epidemiological trends as well as the status of the cholera vaccine stockpile, and will review this decision regularly.

UNICEF delivers lifesaving supplies to Syria to halt the spread of cholera

DAMASCUS, 20 October 2022 – UNICEF delivered lifesaving health and water, hygiene, and sanitation supplies to Syria earlier this week to scale up efforts to halt the cholera outbreak. The supplies included acute watery diarrhoea (AWD) kits to support health facilities and communities in treating 36,000 moderate and severe AWD cases, and aqua tabs to help 350,000 people to treat water for their households’ needs...

Cholera threat ‘close to a death sentence’ for children with severe acute malnutrition in Haiti as food insecurity worsens

PORT-AU-PRINCE/PANAMA/NEW YORK, 14 October 2022 – Nearly 100,000 children under the age of five who are already suffering from severe acute malnutrition -also known as severe wasting - are especially vulnerable to the ongoing cholera outbreak affecting Haiti, UNICEF has warned.

At a time when much of the country is facing growing food insecurity, acutely malnourished children have weakened immune systems and they are at least three times more likely to die if they contract cholera, further reinforcing the need for urgent action to contain the disease.

Since cholera was first reported on 2 October 2022, there have been 357 suspected cases with more than half of these in children under the age of 14. Children aged between one and four years are at the greatest risk...

Women, Children, Adolescent Health

Staggering backsliding across women’s, children’s and adolescents’ health revealed in new UN analysis

COVID-19, conflict, climate crises exacerbate setbacks for childhood and adolescent prospects, women’s rights

News release
18 October 2022, Berlin

A new UN report shows that women’s and children’s health has suffered globally, as the impacts of conflict, the COVID-19 pandemic and climate change converge with devastating effects on prospects for children, young people and women. Data presented in the report show a critical regression across virtually every major measure of childhood well-being, and many key indicators of the Sustainable Development Goals (SDGs). Since the last Every Woman Every Child Progress Report published in 2020, food insecurity, hunger, child marriage, risks from intimate partner violence, and adolescent depression and anxiety have all increased.
An estimated 25 million children were un- or under-vaccinated in 2021 – 6 million more than in 2019 - increasing their risk of contracting deadly and debilitating diseases. Millions of children missed out on school during the pandemic, many for more than a year, while approximately 80% of children in 104 countries and territories experienced learning-loss because of school closures. Since the start of the global pandemic, 10.5 million children lost a parent or caregiver to COVID-19.

“At the core of our unkept promise is the failure to address the gaping inequities at the root of global crises, from the COVID-19 pandemic to conflicts and the climate emergency. The report describes the impacts of these crises on women, children and adolescents, from maternal mortality to education losses to severe malnutrition,” said Antonio Guterres, United Nations Secretary-General.

The report provides wide-ranging evidence that children and adolescents face wildly divergent chances of leading a healthy life simply based on where they are born, their exposure to conflict, and the economic circumstances of their families. For example:

▪ A child born in a low-income country has an average life expectancy at birth of around 63 years, compared to 80 in a high-income country. This devastating 17-year survival gap has changed little over recent years. In 2020, 5 million children died even before the age of 5, mostly from preventable or treatable causes. Meanwhile, most maternal, child, and adolescent deaths and stillbirths are concentrated in just two regions – sub-Saharan Africa and South Asia.

▪ More than 45 million children had acute malnutrition in 2020, a life-threatening condition which leaves them vulnerable to death, developmental delays and disease. Nearly three-quarters of these children live in lower-middle-income countries. A staggering 149 million children were stunted in 2020. Africa is the only region where the numbers of children affected by stunting increased over the past 20 years, from 54.4 million in 2000 to 61.4 million in 2020.

▪ The six countries with the highest numbers of internally displaced persons – Afghanistan, the Democratic Republic of the Congo, Ethiopia, Sudan, the Syrian Arab Republic and Yemen – are also among the top 10 food insecure countries.

▪ A woman in sub-Saharan Africa has around a 130 times higher risk of dying from causes relating to pregnancy or childbirth than a woman in Europe or North America. Coverage of antenatal care, skilled birth attendance, and postnatal care is far from reaching all women in low- and middle-income countries, leaving them at elevated risk of death and disability.

▪ Millions of children and their families are experiencing poor physical and mental health from recent humanitarian disasters in Afghanistan, Ethiopia, Pakistan, Somalia, Ukraine and Yemen. In 2021, a record 89.3 million people worldwide were driven from their homes by war, violence, persecution, and human rights abuse.

The report calls upon the global community to address this damaging trajectory and protect the promises made to women, children, and adolescents in the Sustainable Development Goals. In particular, it advocates for countries to continue investing in health services, to address all crises and food insecurity, and empower women and young people around the world.

:::::::

Protect the promise: 2022 progress report on the Every Woman Every Child Global Strategy for Women’s, Children’s and Adolescents’ Health (2016–2030)
WHO, UNICEF, UNFPA, Partnership for Maternal, Newborn & Child Health (PMNCH) and Countdown to 2030
The report is a bi-annual summary of progress in response to the UN Secretary General's Every Woman Every Child Global Strategy for Women, Children's and Adolescents' Health. The most comprehensive synthesis of evidence on the current state of maternal, newborn, child and adolescent health, it updates the last Every Woman Every Child Global Strategy Progress Report published in 2020.

Featured Journal Content

**Vaccine**
Volume 40, Issue 42 pages 6001-6188 (6 October 2022)
[https://www.sciencedirect.com/journal/vaccine/vol/40/issue/42](https://www.sciencedirect.com/journal/vaccine/vol/40/issue/42)

*Review article Full text access*

**Country immunization policies for refugees across 20 low-middle income and 20 high-income countries**

Jad A. Elharake, Saad B. Omer, Jason L. Schwartz
Pages 6017-6022

*Highlights*
- 13/20 LMICs and 14/20 HICs included refugees in their national routine immunization policies.
- Refugees should be included in national routine immunization policies.
- Refugees should be provided with accessible and affordable immunizations.
- Efforts would reduce vaccine-preventable diseases and protect the health of refugee populations—especially during the COVID-19 pandemic.

*Abstract*

In 2020, 26 million refugees resettled in a new country—fleeing their homes due to conflict and persecution. Due to low immunization coverage and underlying health conditions, refugees commonly face an increased risk of contracting vaccine-preventable diseases. We collected and analyzed existing routine immunization policies for refugees across 20 low- and middle-income countries (LMICs) and 20 high-income countries (HICs), each with the highest number of refugees per 1000 residents. Primary and secondary data sources were used to collect policy evidence. Across 20 LMICs, 13 countries specified standing nationwide routine immunization policies for refugees, while 14 out of the 20 HICs included refugees in their national routine immunization programs. LMICs and HICs should include refugees in their national routine immunization policies and provide accessible and affordable immunizations. Such efforts would reduce vaccine-preventable diseases and protect the health of refugee populations—especially during the COVID-19 pandemic.

[Excerpts]
4.1. Implications and lessons

Across both HICs and LMICs, the delivery of affordable routine immunization services for refugees as part of the basic health services through national vaccine programs should be prioritized. For LMICs, given that there are limitations in the countries’ health system capacity (e.g., the lack of much-needed financial and human resources impacts the implementation of national recommendations and policies and the supply of immunization services for refugees), financial and resource support from international organizations is needed. In addition, mobile vaccination clinics, combined health care services, and routine immunization data collection would help bridge immunity gaps, especially in hard-to-reach refugee settings and populations [20].

In HICs, culturally-appropriate and locally-organized routine immunization services may be helpful in reaching refugees in geographic clusters, and would address any language and cultural barriers with navigating a new health care system. Additionally, health care authorities should conduct survey research and longitudinal studies, in collaboration with local and community organizations, to identify, understand, and address potential vaccine hesitancy or knowledge gaps among the refugee population. Lastly, countries, particularly LMICs, must strengthen their disease surveillance systems to evaluate the role of routine immunization programs in reducing VPDs and continuously inform vaccine policy decisions...

4.3. Strengths and limitations

To our knowledge, this is the first study to conduct a comparative analysis of routine immunization policies pertaining to refugees within LMICs and HICs. Limitations of our analysis includes uncertainty regarding the extent to which these national policies have been implemented in practice. Also, because of how secondary data were collected in this research, policies that were unpublished were not included in our data, unless provided by the public health officials contacted. In particular, additional policy information may exist for the 9 LMICs for which responses from WHO-country officers to queries...
were not provided. Also, due to the nature of available immunization policy information, particularly for LMICs, a comprehensive list of specifically available vaccines and the number of vaccine doses offered, which may vary greatly among the different countries, could not be compiled. Additionally, we were unable to compile comprehensive data on refugees being revaccinated, the usage of vaccine cards, or self-referral. Given that our study was focused on national immunization policies, we did not include any regional or local approaches. Lastly, additional research is needed to further understand the continuously evolving landscape of vaccine policies for refugees worldwide, for both the 40 countries included in this analysis and others...

One Health

One Health Joint Plan of Action launched to address health threats to humans, animals, plants and environment
Published on 17 October 2022
Joint Press Release - FAO, UNEP, WHO and WOAH –

17 October 2022, Paris, Geneva, Nairobi, Rome – Today, a new One Health Joint Plan of Action was launched by the Quadripartite – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH, founded as OIE).

This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats. Ultimately, this initiative seeks to improve the health of humans, animals, plants, and the environment, while contributing to sustainable development.

The One Health Joint Plan of Action, developed through a participatory process, provides a set of activities that aim to strengthen collaboration, communication, capacity building, and coordination equally across all sectors responsible for addressing health concerns at the human-animal-plant-environment interface.

The One Health Joint Plan of Action (OH JPA)
The five-year plan (2022-2026) focuses on supporting and expanding capacities in six areas: One Health capacities for health systems, emerging and re-emerging zoonotic epidemics, endemic zoonotic, neglected tropical and vector-borne diseases, food safety risks, antimicrobial resistance and the environment.

This technical document is informed by evidence, best practices, and existing guidance. It covers a set of actions which endeavour to advance One Health at global, regional and national levels. These actions notably include the development of an upcoming implementation guidance for countries, international partners, and non-State actors such as civil society organizations, professional associations, academia and research institutions.

The plan sets out operational objectives, which include: providing a framework for collective and coordinated action to mainstream the One Health approach at all levels; providing upstream policy and
legislative advice and technical assistance to help set national targets and priorities; and promoting multinational, multi-sector, multidisciplinary collaboration, learning and exchange of knowledge, solutions and technologies. It also fosters the values of cooperation and shared responsibility, multi-sectoral action and partnership, gender equity, and inclusiveness...

One Health Joint Plan of Action (2022-2026)
WORKING TOGETHER FOR THE HEALTH OF HUMANS, ANIMALS, PLANTS AND THE ENVIRONMENT
Strategic Plan
- Food and Agriculture Organization of the United Nations
- United Nations Environment Programme
- World Health Organization
- World Organisation for Animal Health
Rome, 2022 :: 86 pages

The OH JPA is structured around six action tracks (areas of action) for addressing key health challenges at the human–animal–plant–environment interface that require a One Health approach. The action tracks are interdependent. They also capture a systems approach required to reduce health threats shared by humans, animals, plants and the environment and contribute to achieving sustainable health and food systems, as well as improved ecosystem management.

Overview
The One Health Joint Plan of Action (2022–2026) (OH JPA) outlines the commitment of the Quadripartite organisations—the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH, founded as OIE)–to collectively advocate and support the implementation of the One Health approach. It builds on, complements and adds value to existing global and regional One Health and coordination initiatives aimed at strengthening capacity to address complex multidimensional health risks with more resilient health systems at global, regional and national level.

::::::
::::::

COVAX – COVID Vaccines

Gavi, Moderna update COVAX supply agreement; agree on access to variant-containing vaccines for lower-income countries

- Gavi and Moderna agree to cancel remaining volumes under existing COVAX supply agreement
- Two parties establish framework for lower-income countries to access up to 100 million doses of variant-containing vaccine (VCV) through COVAX
- Dr Seth Berkley, CEO of Gavi: "This agreement with Moderna represents a critical step for equitable access, helping COVAX adjust its portfolio to current demand and ensuring lower income countries have access to variant-containing vaccines to use where appropriate.”

Geneva, 17 October 2022 – Gavi, the Vaccine Alliance announced today that it had signed an agreement with Moderna related to the supply of COVID-19 vaccines to lower-income countries supported by the Gavi COVAX Advance Market Commitment (AMC). Under the agreement, Gavi and Moderna agree to cancel remaining volumes under their previous agreement in 2022, and establish a framework for lower-income countries to access doses of variant-containing vaccine (VCV) beginning in 2023. Gavi will have the right to access up to 100 million VCV doses, at Moderna’s lowest tiered price, on behalf of AMC participants...

In the two years since the first COVID-19 vaccine received WHO emergency approval in December 2020, COVAX has delivered 1.8 billion doses to 146 countries around the world – the largest and fastest public health rollout in history. This includes nearly 186 million doses of the Moderna vaccine, through both the advance purchase agreement with Moderna and dose donations. This effort has enabled 92 lower-income countries to protect, on average, more than 50% of their populations with two doses of COVID-19 vaccine – and protect the majority of those at highest risk such as health care workers and the elderly...

A key element to COVAX’s ability to deploy COVID-19 vaccines at a historically high rate has been its ability to adapt to an unpredictable and rapidly changing pandemic environment. This latest agreement is part of an on-going effort to actively manage COVAX’s portfolio to meet countries’ evolving needs and be prepared for unexpected future scenarios by rephasing, resizing and updating supply agreements with manufacturers and donors.

Recognising that countries’ needs are still constantly changing, COVAX has also updated its allocation model so that AMC participants can now request – and be rapidly allocated –
**doses at any time.** To-date, COVAX has been able to make doses available for 100% of the country requests received through this “rolling allocation” process.

---

**Statement on the thirteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic**

18 October 2022

**Statement**

Report of the thirteenth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the coronavirus 2019 disease (COVID-19) pandemic, held on Thursday, 13 October 2022, from 12:00 to 16:00 CEST.

The **WHO Director-General** concurs with the advice offered by the Committee regarding the ongoing COVID-19 pandemic and determines that the event continues to constitute a Public Health Emergency of International Concern (PHEIC).

The WHO Director-General considered the advice provided by the Committee regarding the proposed Temporary Recommendations. The set of Temporary Recommendations issued by the WHO Director-General is presented at the end of this statement.

*Excerpts*

**Deliberative session**

The Committee acknowledged progress in controlling the outbreak in many countries with the number of severe cases and deaths substantially decreased and high levels of population immunity achieved in many countries through vaccination and/or infection, leading to resumption of economic and social life and lifting of most COVID-19-related restrictions.

However, the Committee was concerned that despite being well into the third year of the pandemic, there remained considerable uncertainties as to the further trajectory of the virus as well as to the genetic and antigenic characteristics and clinical impact of future variants. The Committee also remained concerned over the increasing challenges in quantifying the broader COVID-19 burden on health systems including thrombotic and endocrine complications as well as the extent and burden of Post COVID-19 condition. More broadly, Committee members recognized that many health systems remain under pressure because of other health emergencies and competing health priorities, in addition to the challenges posed by COVID-19. In this context, the Committee expressed concern about the heavy workload and associated burnout being experienced by health care workers worldwide, leading to an increased deficit in the workforce.

The Committee also expressed concern over the reduction in epidemiological and laboratory surveillance for SARS-CoV-2. This impedes assessments of currently circulating and emerging variants of the virus, including genomic and phenotypic assessments, and hinders abilities to interpret trends in transmission and burden of disease. The Committee continued to highlight the importance of expediting the integration of COVID-19 surveillance into other routine surveillance systems, including the integration of COVID-19 surveillance with the surveillance of other respiratory pathogens, community-based surveillance, and the potential value of supplementing it with wastewater surveillance.

The Committee acknowledged the ongoing work of WHO and partners to achieve WHO- and SAGE-recommended vaccination targets, particularly reaching 100% vaccination
coverage among those in the highest priority groups. Nonetheless, concern remained as to the lack of sharing of data needed to monitor progress of vaccination campaigns, and—where data is available—the persistent inequities in access to vaccines as well as to WHO-recommended therapeutics. These inequities in access have resulted in many COVID-19 deaths that may have otherwise been avoided. The Committee acknowledged the disruption the pandemic continues to have on routine (non-COVID-19) immunization activities, which has repeatedly manifested as outbreaks of vaccine-preventable diseases in areas where essential immunization activities have lapsed since early 2020.

The Committee recognized that many national COVID-19 policies reflect a perception that the emergency may be over and that governments, healthcare workers and societies in general are experiencing "COVID-19 fatigue." The Committee therefore emphasized the need to enhance social listening and community engagement as means to better tailor risk communications and contextualize policies, that will help people to continue to take the actions needed to protect their health. The Committee highlighted persistent misinformation related to many aspects of the COVID-19 response, particularly the dangers posed by pervasive disinformation on vaccination, vaccine hesitancy and the convergence of organized anti-vaccination efforts in many countries.

**Status of the Public Health Emergency of International Concern**

...In advising the WHO Director-General that the event still constitutes a PHEIC, the Committee developed the following arguments underpinning its advice.

First, the clear decoupling in incident cases and severe disease has led to a perception in communities that the emergency may be over and that measures to reduce transmission are no longer warranted. Although the number of weekly deaths reported to WHO is near the lowest since the pandemic began, it remains high compared with other respiratory viruses, and the added burden of COVID-19 related complications and Post COVID-19 Condition is also high and its full impact not completely understood. The evolution of the outbreak during the upcoming winter season in the Northern hemisphere must also be considered.

Second, although ongoing evolution of the virus is expected to continue, the genetic and antigenic characteristics of future variants cannot yet be reliably predicted, partly due to the current gaps in global surveillance that hinder identifying and evaluating these changes early. In addition, the ongoing virus evolution, with potentially increased properties of immune escape, may pose challenges to current vaccines and therapeutics.

Finally, inequities in access to COVID-19 vaccines and therapeutics persist between and within countries, such that the highest priority groups do not currently have access to safe and effective vaccine and therapeutics everywhere.

Given the above considerations, the Committee concurred that continued coordination of the international response is necessary to reliably evaluate the health impact of the pandemic, monitor and assess the evolution of the virus and the impact of future variants, to intensify efforts to ensure access to safe and effective countermeasures, and to enhance tailored risk communication and community engagement activities.
Overall, the Committee considered that the situation remains dynamic and requires frequent reassessments, and that the termination of the PHEIC, when considered feasible, should be implemented as safely as possible.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*


**Weekly Epidemiological and Operational updates**

*Last update: 21 Oct 2022*

**Confirmed cases:** 623 893 894

**Confirmed deaths:** 6 553 936

**Vaccine doses administered:** 12 814 704 622

---

**Weekly epidemiological update on COVID-19 – 19 October 2022**

**Overview**

Globally, the number of new weekly cases decreased by 6% during the week of 10 to 16 October 2022, as compared to the previous week, with over 2.9 million new cases reported. The number of new weekly deaths decreased by 17%, as compared to the previous week, with about 8300 fatalities reported.

As of 16 October 2022, 621 million confirmed cases and 6.5 million deaths have been reported globally.

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 16 October 2022**
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 21 July 2022
[New additions; Full scale view available at title link above]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 22 Oct 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

- 41 vaccines approved for use by at least one national regulatory authority
- 11 vaccines in WHO’s Emergency Use Listing
- 1.80bn doses shipped through COVAX to 146 countries
- $2–$40 reported vaccine price range per dose
- 17.9bn doses secured globally
- 44K novel oral antiviral therapeutic treatments arrived in 3 countries

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

See also visualization on Vaccine Access and Vaccine Affordability
COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

---

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Pledged doses</th>
<th>Total shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>842,900,000</td>
<td>800,000,000</td>
</tr>
<tr>
<td>China</td>
<td>173,000,000</td>
<td>166,000,000</td>
</tr>
<tr>
<td>Germany</td>
<td>124,000,000</td>
<td>118,000,000</td>
</tr>
<tr>
<td>France</td>
<td>100,000,000</td>
<td>95,000,000</td>
</tr>
<tr>
<td>Spain</td>
<td>100,000,000</td>
<td>94,000,000</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>77,000,000</td>
<td>72,000,000</td>
</tr>
<tr>
<td>Australia</td>
<td>60,000,000</td>
<td>60,000,000</td>
</tr>
<tr>
<td>Japan</td>
<td>60,000,000</td>
<td>60,000,000</td>
</tr>
<tr>
<td>Canada</td>
<td>51,000,000</td>
<td>51,000,000</td>
</tr>
</tbody>
</table>

Number of Doses

Remaining: 710,936,898
Total Shipped: 1,483,933,360

Date updated on October 21st, 2020
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
15 Oct 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 120M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.9B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 370M
Other Delivered (Number of Doses): 400M
Total Delivered (Number of Doses): 770M
Total Administered (Number of Doses): 520M

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.


Our World in Data
:: 68.4% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.86 billion doses have been administered globally, and 2.66 million are now administered each day.
:: 23.3% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.

FDA
Press Announcements
No new digest content identified.
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age (updated)
CHMP, Last updated: 19/10/2022

News: EMA recommends approval of second adapted Spikevax vaccine (new)
CHMP, Last updated: 19/10/2022

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

Latest Updates [Selected]

News

New Omicron sub-lineage likely to cause further increase in covid-19 cases
Epidemiological update - 21 Oct 2022

News

Ebola outbreak in Uganda, as of 21 October 2022
Epidemiological update - 21 Oct 2022

News

High monkeypox vaccine acceptance among male users of smartphone-based online gay-dating apps in Europe
News - 21 Oct 2022

News

Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 19 Oct 2022

Monkeypox multi-country outbreak - second update
Risk assessment
18 Oct 2022

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on : 23 October 2022, 08:00 IST (GMT+5:30)
(1) Status change since yesterday

<table>
<thead>
<tr>
<th>Active</th>
<th>Discharged</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>23432</td>
<td>44090349</td>
<td>528961</td>
</tr>
</tbody>
</table>

(98.76%) (0.05%) (1.18%)

COVID-19 Vaccination as on : 23 October 2022, 08:00 IST (GMT+5:30)

Total Vaccination : 2,19,55,98,943 (2,10,617 ↑)

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.
China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

:::
:::
:::

PHEIC

Monkeypox

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Multi-country outbreak of monkeypox, External situation report #8 - 19 October 2022

<table>
<thead>
<tr>
<th>Risk assessment</th>
<th>Laboratory confirmed cases</th>
<th>Deaths</th>
<th>Countries/areas/territories</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global risk – Moderate</td>
<td>73 437</td>
<td>29</td>
<td>109</td>
</tr>
<tr>
<td>WHO Regional risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Region, Region of the Americas – High</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African Region, Eastern Mediterranean Region, Southeast Asia Region – Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific Region – Low</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Highlights**

:: During the week of 10 October to 16 October 2022, the number of monkeypox cases reported in the Regions of Europe and the Americas continue to decline, driving the overall downward trend observed since August 2022.
:: Since the last Situation Report published on 5 October 2022, 4537 new cases (6.6% increase in total cases) and four new deaths have been reported.
:: WHO has circulated, through its Regional Offices, a protocol to support the in-depth case investigation form (CIF) for Member State use, to better understand case characteristics and transmission dynamics.
:: Multi-disciplinary country support missions have been conducted by WHO in the past two weeks to lend support to optimizing surveillance and other areas of monkeypox response, including in Ghana, Nigeria, and (remotely) to the Gulf Centre for Disease Prevention and Control for a Gulf Coordinating Council (GCC) States regional risk assessment exercise.
:: For strategic planning and global support, WHO is appealing for US$ 33.82 million to take immediate action to stop the monkeypox outbreak in collaboration with the Member States, partners, and other stakeholders...

:::
:::
:::

PHEIC
Polio

Polio this week as of 19 Oct 2022 - GPEI
:: In Berlin, Germany, this week at the World Health Summit, global leaders confirmed US$2.6 billion in funding toward the GPEI’s 2022-2026 Strategy, at a pledging moment co-hosted by Germany’s Federal Ministry for Economic Cooperation and Development (BMZ). “No place is safe until polio has been eradicated everywhere. As long as the virus still exists somewhere in the world, it can spread— including in our own country. We now have a realistic chance to eradicate polio completely, and we want to jointly seize that chance,” said Svenja Schulze, Federal Minister for Economic Cooperation and Development, Germany. “Germany will remain a strong and committed partner in the global fight against polio. This year, it is providing 35 million euros for this cause. And next year we plan to further strengthen our efforts and support GPEI with 37 million euros—pending parliamentary approval.”
:: 24 October is World Polio Day, a global day to raise awareness and resources for the worldwide effort to eradicate polio. Communities, Rotarians, civil society, governments and partners around the world are organizing events to mark the occasion and draw attention to the opportunity to rid the world of an infectious disease once and for all, including at a special event at WHO’s European Regional Office with keynote speakers from partners and the Global Certification Commission for Polio Eradication.
:: 21-22 October: World Polio Day and Beyond: a healthier future for mothers and children. A joint Rotary/WHO in-person and digital event at WHO in Geneva. WHO Director-General Dr. Tedros Adhanom Ghebreyesus and Rotary International President for 2022-2023 Jennifer Jones will discuss the work the two organizations have done together for decades to eradicate polio and how they will continue to work together on a healthier future for mothers and children.

Summary of new polioviruses this week:
- Pakistan: two WPV1 positive environmental samples
- Benin: One cVDPV2 case
- DR Congo: 18 cVDPV1 cases and 17 cVDPV2 cases
- Malawi: one cVDPV1 case
- Niger: two cVDPV2 positive environmental samples
- Senegal: one cVDPV2 positive environmental sample
- Togo: one cVDPV2 positive environmental sample
- Yemen: five cVDPV2 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
Ethiopia - Situation Report, 15 Oct 2022

Somalia
No new digest content identified.
Ukraine
Situation Highlights  12 Oct 2022


WHO & Regional Offices  [to 22 Oct 2022]
https://www.who.int/news
Selected News/Announcements/Statements
21 October 2022
Statement
World Health Organization (WHO) response to the External Evaluation of the Access to COVID-19 Tools Accelerator (ACT-A)

20 October 2022
Departmental news
Building next generation sequencing capacity for SARS-CoV-2 through workforce strengthening in Kyrgyzstan

20 October 2022
Departmental news
WHO announces the update of the Consolidated Guidelines on HIV Testing Services (update 2022–23)

19 October 2022
Departmental news
Oman first country in the Eastern Mediterranean Region to eliminate mother-to-child transmission of HIV and syphilis

19 October 2022
News release
Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide

18 October 2022
News release
Global leaders commit US$ 2.6 billion at World Health Summit to end polio

18 October 2022
Statement
Statement on the thirteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

18 October 2022
News release
Staggering backsliding across women’s, children’s and adolescents’ health revealed in new UN analysis
18 October 2022
Departmental news
**Launch of major new progress report on women and children’s health**

17 October 2022
Departmental news
**Sustaining Action Against Antimicrobial Resistance: A Case Series of Country Experiences**

17 October 2022
News release
**UNICEF and WHO welcome KSrelief funding for measles and polio epidemics prevention**

17 October 2022
News release
**One Health Joint Plan of Action launched to address health threats to humans, animals, plants and environment**

------

**WHO Director General Speeches** [selected]
[https://www.who.int/director-general/speeches](https://www.who.int/director-general/speeches)

*Selected Speeches*
21 October 2022
Speech
**WHO Director-General’s remarks at the World Polio Day 2022 and Beyond event – 21 October 2022**

20 October 2022
Speech
**WHO Director-General's opening remarks at 3rd meeting of the IHR Emergency Committee: multi-country outbreak of monkeypox - 20 October 2022**

19 October 2022
Speech
**WHO Director-General's opening remarks at media briefing – 19 October 2022**

19 October 2022
Speech
**WHO Director-General's opening remarks at the 11th Meeting of the WHO Member State mechanism on substandard and falsified medical products - 19 October 2022**

18 October 2022
Speech
**WHO Director-General's opening remarks at "Protect the Promise: Equal access and opportunity for every woman, child and adolescent", World Health Summit - 18 October 2022**
Remarks

WHO Director-General’s closing remarks at the World Health Summit: Moving into the Future: Making the Political Choice for Health - 18 October 2022

:::

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: Ghana targets over 7 million in polio vaccination drive 21 October 2022
:: COVID-19 vaccination roll-out stagnates in Africa 20 October 2022

Brazzaville – COVID-19 vaccination coverage has stagnated in half of African countries, while the number of doses administered monthly declined by over 50% between July and September, a World Health Organization (WHO) analysis finds. Although Africa is far from reaching the year-end global target of protecting 70% of the population, modest progress has been made in vaccinating high-risk population groups, particularly the elderly...
:: Sierra Leone targets cervical cancer mortality by vaccinating girls 11 October 2022

WHO Region of the Americas PAHO
:: Statement on the thirteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic 19 October 2022 – The WHO Director-General has the pleasure of transmitting the Report of the thirteenth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the coronavirus 2019 disease (COVID-19) pandemic, held on Thursday, 13 October 2022, from 12:00 to 16:00 CEST. The WHO Director-General...
:: Discussions at the Cuba Salud 2022 International Health Convention Focus on Post-pandemic Health and Achieving the Sustainable Development Goals
Havana, Cuba, 19 October 2022 – The current challenges facing health systems after the COVID-19 pandemic, as well as how to achieve the Sustainable Development Goals (SDGs) by 2030, were the focus of a high-level panel on the second day of the fourth edition of Cuba Salud 2022, an international health convention that continues in Havana...
:: Statement: Circulation of “Public Warning Alert” on COVID-19 vaccines fraudulently using PAHO’s name and logo
Washington, D.C. (PAHO) – A social media video from an unidentified source unlawfully using the logo and name of the Pan American Health Organization (PAHO) is circulating in English-speaking Caribbean countries as a “Public Warning Alert” on COVID-19 vaccination in children. PAHO would like to inform the public that the message does not reflect...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO
:: 20 October 2022  News release
:: While heavily pregnant, Darina fled from Ukraine to Bulgaria, where many hands guided her towards critical health care
:: 20 October 2022  News release
Collaboration is key to countering online misinformation about noncommunicable diseases – new WHO/Europe toolkit shows how
:: 20 October 2022 News release
Joining forces to meet unprecedented need: How Bulgaria has responded to the Ukrainian refugee crisis
:: 19 October 2022 News release
How WHO is supporting Azerbaijan in improving rehabilitation and assistive technology services

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

20 October 2022 | Rift Valley fever - Mauritania
19 October 2022 | Cholera - Lebanon
17 October 2022 | Malaria - Pakistan

WHO Events
https://www.who.int/news-room/events/1
[Selected]
Strategic & Technical Advisory Group on Infectious Hazards with Pandemic and Epidemic Potential (STAG-IH) - October 2022
24 – 26 October 2022

New WHO Publications
https://www.who.int/publications/i
Selected Titles
18 October 2022
Report of the Regional Director: the work of WHO in the Western Pacific Region, 1 July 2021 - 30 June...

18 October 2022
Informal consultation on end-game challenges for trachoma elimination

17 October 2022
Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV...
17 October 2022

**Good practice statement on the use of variant-containing COVID-19 vaccines**

::::::

**CDC/ACIP [U.S.] [to 22 Oct 2022]**

http://www.cdc.gov/media/index.html

https://www.cdc.gov/vaccines/acip/index.html

**Latest News Releases**

**CDC Director Tests Positive For COVID-19**

October 22, 2022  
Last night, CDC Director Dr. Rochelle Walensky tested positive for COVID-19. She is up to date with her vaccines. Dr. Walensky is experiencing mild symptoms.

**ACIP Immunization Schedule Vote**

October 20, 2022  
Today, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended updates to the 2023 childhood and adult immunization schedules, which includes incorporating additional information for approved or authorized COVID-19 vaccines.

**CDC Allows Novavax Monovalent COVID-19 Boosters for Adults Ages 18 and Older**

Wednesday, October 19, 2022

**Inequities Found in Flu Vaccine Uptake**

Tuesday, October 18, 2022

**The U.S. Response to Ebola Outbreaks in Uganda**

Tuesday, October 18, 2022

::::::

**ACIP Meetings**

*Next ACIP Meeting*

No meetings identified.

::::::

**MMWR Weekly: Current Volume (71)**

October 21, 2022 / No. 42

PDF of this issue

- Progress Toward Poliomyelitis Eradication — Pakistan, January 2021–July 2022
- Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel — United States, 2021–22
- Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2
Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
- Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022
- Ocular Monkeypox — United States, July–September 2022
- Monkeypox Virus Infection Resulting from an Occupational Needlestick — Florida, 2022

Coronavirus Disease 2019 (COVID-19) - CDC
Approximately 15 announcements/reports/data summaries.

Africa CDC [to 22 Oct 2022]
http://www.africacdc.org/
News
Call for Applications: African Union (AU) COVID-19 Vaccination Bingwa Initiative – Eastern Africa Region
19 October 2022

China CDC
http://www.chinacdc.cn/en/
National Health Commission of the People’s Republic of China [to 22 Oct 2022]
http://en.nhc.gov.cn/
News
Oct 22: Daily briefing on novel coronavirus cases in China
On Oct 21, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 215 new cases of confirmed infections.

National Medical Products Administration – PRC [to 22 Oct 2022]
http://english.nmpa.gov.cn/
Chinese mainland reports 158 new local confirmed COVID-19 cases
2022-10-21
The Chinese mainland on Thursday reported 158 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-10-21 / No. 42 AGING AND HEALTH ISSUE
View PDF of this issue
- Preplanned Studies: Greenness and Asthma in the Middle-Aged and Elderly Population in a Prospective Cohort Study — China, 2011–2018
- Preplanned Studies: Association Between Physical Activity and Physical Fitness Among Adults Aged 40 to 79 Years — Beijing, China, 2020–2021
- Preplanned Studies: Changes in Sleep Duration and the Risk of Cognitive Impairment Among Older Adults Aged 65 Years and Over — China, 2014–2019
- Vital Surveillances: Trends in the Prevalence of Cognitive Impairment Among Older Adults Aged 65 to 105 Years — China, 2002–2018

Organization Announcements

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 22 Oct 2022]
https://alleninstitute.org/news-press/
News
Allen Institute names Chris Beaudoin as Chief Operations Officer
October 21, 2022
Beaudoin brings more than two decades of leadership experience in the healthcare field to the Institute

BMGF - Gates Foundation [to 22 Oct 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 22 Oct 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Antibiotics
October 18, 2022  Press Release, Written by Gates MRI
Merck and the Bill & Melinda Gates Medical Research Institute today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB).
Developing Tuberculosis Vaccines for People with HIV: Consensus Statements from an International Expert Panel

October 11, 2022  Publication

Gate MRI's Head of Vaccine Development, Alex Schmidt, joins a panel of international experts on a recent consensus statement for the development of TB vaccines in those with HIV. The paper outlines recommendations for vaccine developers on which vaccines, patient populations, and efficacy endpoints to prioritize when investigating a TB vaccine in individuals with HIV as well as ethical and regulatory factors to consider.

CARB-X  [to 22 Oct 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 22 Oct 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – October 2022 is now posted here
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations  [to 22 Oct 2022]
http://cepi.net/
Latest News
News; Publications
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 22 Oct 2022]
https://cioms.ch/
News; Publications
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 22 Oct 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center  [to 22 Oct 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP**  [to 22 Oct 2022]  
http://www.edctp.org/  
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials  
No new digest content identified.

**Emory Vaccine Center**  [to 22 Oct 2022]  
http://www.vaccines.emory.edu/  
Vaccine Center News  
No new digest content identified.

**European Vaccine Initiative**  [to 22 Oct 2022]  
http://www.euvaccine.eu/  
Latest News, Events  
No new digest content identified.

**Evidence Aid**  [to 22 Oct 2022]  
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.  
http://www.evidenceaid.org/  
Rapid, point-of-care antigen and molecular-based tests for SARS-CoV-2 (research up to 8 March 2021)  
Added October 18, 2022  
Transmission of Middle East Respiratory Syndrome (MERS) Coronavirus infections among healthcare workers in the Middle East  
Added October 18, 2022  
Risk factors for communicable disease outbreaks in complex humanitarian emergencies  
Added October 17, 2022

**Fondation Merieux**  [to 22 Oct 2022]  
http://www.fondation-merieux.org/  
News, Events  
No new digest content identified

**Gavi**  [to 22 Oct 2022]  
https://www.gavi.org/  
News Releases
17 October 2022

**Gavi, Moderna update COVAX supply agreement; agree on access to variant-containing vaccines for lower-income countries**

- Gavi and Moderna agree to cancel remaining volumes under existing COVAX supply agreement
- Two parties establish framework for lower-income countries to access up to 100 million doses of variant-containing vaccine (VCV) through COVAX
- Dr Seth Berkley, CEO of Gavi: “This agreement with Moderna represents a critical step for equitable access, helping COVAX adjust its portfolio to current demand and ensuring lower income countries have access to variant-containing vaccines to use where appropriate.”

**GHIT Fund** [to 22 Oct 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

**Global Fund** [to 22 Oct 2022]
News & Stories
No new digest content identified.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 22 Oct 2022]
https://www.glopid-r.org/news/
News
**GloPID-R General Assembly: October 19-20 in Berlin**
October 18, 2022

**Hilleman Laboratories** [to 22 Oct 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

**HHMI - Howard Hughes Medical Institute** [to 22 Oct 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

**Human Vaccines Project** [to 22 Oct 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.
IAVI  [to 22 Oct 2022]
https://www.iavi.org/
Latest News
No new digest content identified.

ICRC  [to 015 Oct 2022]
What’s New  [Selected]  •
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
ICMRA COVID-19 Working Group - Summary of Achievements
21 October 2022

IFFIm
http://www.iffim.org/
Press Releases/Announcements
How the World Bank built trust in vaccine bonds
21 Oct 2022
Q&A with Doris Herrera-Pol and Heike Reichelt.

IFRC  [to 22 Oct 2022]
Press Releases [Selected]
Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide
19/10/2022 | Press release
[See Milestones above for detail]

Institut Pasteur  [to 22 Oct 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration  [to 22 Oct 2022]
News
No new digest content identified.
ISC / International Science Council [to 22 Oct 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Current
News
Global developments on research evaluation and assessment
20.10.2022 Blogs
An update on the ISC partnership with the Global Young Academy (GYA) and InterAcademy Partnership (IAP) on research evaluation.

5 Key Takeaways from NASEM’s Webinar: ‘Censorship and the Right to Information during the Pandemic’
19.10.2022 News

Call for expressions of interest to establish regional nodes of the African Open Science Platform (AOSP)
17.10.2022

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC [to 22 Oct 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IFI [to 22 Oct 2022]
http://www.ivi.int/
IFI News & Announcements
IVI gathers member countries for 2022 State Forum and celebrates its 25th anniversary with key partners

IVI launches Global Advisory Group of Experts chaired by Dr. Deborah Birx
October 20, 2022, SEOUL, Republic of Korea — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, launched its Global Advisory Group of Experts today during its inaugural meeting held in Seoul, Republic of Korea. Dr. Deborah Birx, former U.S. Special Representative for Global Health Diplomacy and White House Coronavirus Response Coordinator, chairs the GAGE and other members include subject matter experts across international diplomacy, government affairs, international corporations and non-profits, and public policy...
No new digest content identified.

MSF/Médecins Sans Frontières [to 22 Oct 2022]
http://www.msf.org/
Latest [Selected Announcements]
Syria
Cholera spreads across Syria putting vulnerable people at serious risk
Project Update 21 Oct 2022

Haiti
Haiti on the verge of health disaster
Press Release 21 Oct 2022

National Academy of Medicine - USA [to 22 Oct 2022]
https://nam.edu/programs/
News [Selected]
National Academy of Medicine Elects 100 New Members
October 17, 2022

National Academy of Sciences - USA [to 22 Oct 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 22 Oct 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 22 Oct 2022]
http://www.nih.gov/
News Releases
Early HIV diagnosis and treatment important for better long-term health outcomes
October 21, 2022 — When HIV diagnosis and treatment are delayed, HIV continues to replicate.

Three-dose hepatitis B vaccine regimen protects people with HIV
October 20, 2022 — Finding is part of an ongoing clinical trial.
**PATH** [to 22 Oct 2022]
https://www.path.org/media-center/

**Press Releases**

**Ministry of Health Rolls Out New Plan for Strengthening Private-Sector Engagement in Vietnam’s HIV Program**

October 20, 2022 by PATH

The Vietnam Ministry of Health and USAID through its supported project, PATH STEPS, outlined an implementation road map for Vietnam’s first-ever HIV private-sector engagement plan.

---

**Rockefeller Foundation** [to 22 Oct 2022]
https://www.rockefellerfoundation.org/

**Selected Reports/Press Releases**

No new digest content identified.

---

**Sabin Vaccine Institute** [to 22 Oct 2022]
https://www.sabin.org/press/

**Latest News & Press Releases**

No new digest content identified.

---

**UNAIDS** [to 22 Oct 2022]
http://www.unaids.org/en

**Selected Press Releases/Reports/Statements**

No new digest content identified.

---

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 22 Oct 2022]

**News Releases**

No new digest content identified.

---

**UNICEF** [to 22 Oct 2022]
https://www.unicef.org/media/press-releases

**Press Releases, News Notes, Statements** [Selected]

**Press release**

21 October 2022

**More than 1.5 million children at risk as devastating floods hit Nigeria**


ABUJA/NEW YORK, 21 October 2022– More than 2.5 million people in Nigeria are in need of humanitarian assistance – 60 per cent of which are children – and are at increased risk of waterborne diseases, drowning and malnutrition due to the most severe flooding in the past decade, UNICEF warned today. The floods, which have affected 34 out of the 36...

**Press release**
21 October 2022

**More than 1 in 9 children in flood-affected areas of Pakistan suffering from severe acute malnutrition**

**ISLAMABAD, 21 October 2022** — In the aftermath of the devastating floods in Pakistan, health facilities are reporting alarming levels of severe acute malnutrition among children in affected areas, UNICEF warned today. More than 1 in 9 children under five admitted to health facilities in flood-affected areas of Sindh and Balochistan were found to be...

**News note**
20 October 2022

**UNICEF delivers lifesaving supplies to Syria to halt the spread of cholera**

**DAMASCUS, 20 October 2022** – UNICEF delivered lifesaving health and water, hygiene, and sanitation supplies to Syria earlier this week to scale up efforts to halt the cholera outbreak. The supplies included acute watery diarrhoea (AWD) kits to support health facilities and communities in treating 36,000 moderate and severe AWD cases, and aqua tabs...

**Press release**
19 October 2022

**UNICEF Goodwill Ambassador Priyanka Chopra Jonas meets children suffering from severe malnutrition in Kenya**

**NAIROBI/NEW YORK, 20 October 2022** – UNICEF Goodwill Ambassador Priyanka Chopra Jonas travelled to northern Kenya this week to meet children suffering from severe acute malnutrition as a result of prolonged drought across the Horn of Africa. During the two-day visit, Chopra Jonas travelled to Turkana County – among 15 drought-affected counties in...

**Press release**
18 October 2022

**Global leaders commit $US2.6 billion at World Health Summit to end polio**

**BERLIN, 18 October 2022** – Today, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s (GPEI) 2022-2026 Strategy to end polio at a pledging moment co-hosted by Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) at the World Health Summit in Berlin. The funding will support...

**Remarks**
18 October 2022

**UNICEF warns of unprecedented numbers of child deaths in Somalia**

**DOLLOW, Somalia, 18 October 2022** – “Today in Somalia, every single minute of every single day, a child is admitted to a health facility for treatment of severe acute malnutrition. The latest admission rates from August show 44,000 children admitted with severe acute malnutrition. That is a child per minute. "A child whose mother has walked for...
UNICEF and WHO welcome KSrelief funding for measles and polio epidemics prevention


BERLIN, 17 October 2022 – The World Health Organization (WHO) and UNICEF welcomed today funding agreements from the King Salman Humanitarian Aid and Relief Centre (KSRelief) valued at US$ 10 million to further bolster polio and measles programmes in eight countries. The agreement was signed on the sidelines of the World Health Summit in Berlin....

Staggering backsliding across women’s, children’s and adolescents’ health revealed in new UN analysis


Berlin, 18 October 2022 – A new UN report shows that women’s and children’s health has suffered globally, as the impacts of conflict, the COVID-19 pandemic and climate change converge with devastating effects on prospects for children, young people and women. Data presented in the report show a critical regression across virtually every major...

Child poverty across eastern Europe and Central Asia soars by 19 per cent, as Ukraine war and rising inflation drive four million children into poverty - UNICEF


GENEVA/NEW YORK, 17 October 2022 – The war in Ukraine and rising inflation have driven an additional four million children across eastern Europe and Central Asia into poverty, a 19 per cent increase since 2021, according to a new UNICEF study published today. The impact of the war in Ukraine and subsequent economic downturn on child poverty in...

Cholera threat 'close to a death sentence' for children with severe acute malnutrition in Haiti as food insecurity worsens


PORT-AU-PRINCE/PANAMA/NEW YORK, 14 October 2022 – Nearly 100,000 children under the age of five who are already suffering from severe acute malnutrition -also known as severe wasting - are especially vulnerable to the ongoing cholera outbreak affecting Haiti, UNICEF has warned. At a time when much of the country is facing growing food insecu

Unitaid [to 22 Oct 2022]
https://unitaid.org/
Featured News
Unitaid issues call for proposals to help avert the most common causes of death among people living with HIV

Vaccine Equity Cooperative [nee Initiative]  [to 22 Oct 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin]  [to 22 Oct 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project  [to 22 Oct 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 22 Oct 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust  [to 22 Oct 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

The Wistar Institute  [to22 Oct 2022]
Press Releases
“The London Patient” Adam Castillejo Speaks at William Way Community Center to Spread Hope for a Future HIV Cure

PHILADELPHIA—(October 20, 2022)—William Way Community Center, Philadelphia FIGHT, BEAT-HIV Delaney Collaboratory, Philadelphia Foundation, The Penn Center for AIDS Research, and The Wistar Institute are proud to announce that “The London Patient” Adam Castillejo will take part in a reception, followed by a panel conversation and Q&A on Wednesday, October 26 from 5:00 to 8:00 p.m. at the William Way Community Center.

WFPHA: World Federation of Public Health Associations  [to 22 Oct 2022]
Driving Pediatric Vaccines Recovery in Europe
Oct 18, 2022
Pediatric vaccination helps protect children and adults against serious, preventable and sometimes life-threatening diseases. Childhood vaccination coverage in Europe has increased in recent decades,...

World Bank [to 015 Oct 2022]
All News
No new digest content identified.

World Customs Organization – WCO [to 22 Oct 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

World Medical Association [WMA] [to22 Oct 2022]
Press Releases
Healthcare discrimination against elderly must end, says WMA
19.10.2022
A call to the medical profession and governments around the world to eliminate all forms of healthcare discrimination against the elderly has come from the World Medical Association. In a new policy document, the WMA says that elderly individuals experience all kinds of discrimination in health care...

World Organisation for Animal Health (OIE) [to 22 Oct 2022]
https://www.oie.int/en/
Press Releases, Statements
Joint Press Release
One Health Joint Plan of Action launched to address health threats to humans, animals, plants and environment
Published on 17 October 2022
The initiative by the Quadripartite - FAO, UNEP, WHO and WOAH – also aims to contribute to sustainable development.
[See Milestones above for detail]

WTO - World Trade Organisation [to22 Oct 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
No new digest content identified.


**ARM [Alliance for Regenerative Medicine]** [to 22 Oct 2022]
Selected Press Releases
No new digest content identified.

**BIO** [to 22 Oct 2022]
Press Releases
No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 22 Oct 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

**ICBA – International Council of Biotechnology Associations** [to 22 Oct 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

**IFPMA** [to 22 Oct 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
IFPMA statement at the 69th session of the WHO EMRO committee on agenda item EM/RC69/14
18 October 2022

**International Alliance of Patients’ Organizations – IAPO** [to 22 Oct 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
Press Releases
IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)
The International Generic and Biosimilar Medicines Association’s (IGBA) newly established CEO Advisory Committee held its first in-person meeting in Geneva this week and had a far-reaching
exchange with the World Health Organization’s (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other WHO leaders. This was the first opportunity for Dr. Tedros to engage in a direct dialogue with the IGBA CEO Advisory Committee following its launch and the admission of IGBA as a non-State actor in official relations with WHO earlier this year.

**PhRMA**  [to 22 Oct 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

::::::
::::::

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

**AstraZeneca**
Press Releases
**IDWeek data reinforces AstraZeneca’s commitment to advance science in vaccines and immune therapies**
20 October 2022
- Additional analyses from TACKLE Phase III treatment trial further demonstrate Evusheld’s potential to reduce COVID-19 severity and mortality
  - Analysis of long-acting antibody Beyfortus across respiratory syncytial virus (RSV) season further underscores the potential of the investigational treatment to be the first and only single-dose preventative option for all infants

**Bharat Biotech**
Press Releases  - No new digest announcements identified

**BioCubaFarma – Cuba**
**Últimas Noticias**  - No new digest announcements identified

**Biological E**
News  - No new digest announcements identified

**BioNTech**
Press Releases
**Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union**
19 October 2022

**CanSinoBIO**
News  - Website not responding at inquiry

**CIGB**
Latest News  - No new digest announcements identified
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
21 October 2022
GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate
The proposed indication is for adults aged 60 years and above to prevent lower respiratory tract diseases (LRTD) caused by RSV.

19 October 2022
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
The ZOSTER-049 extension study shows that Shingrix can provide at least a decade of protection against shingles after initial vaccination

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Medicago
Media - No new digest announcements identified

Merck
News releases
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
October 18, 2022

Moderna
Press Releases
19 October, 2022
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna’s Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
19 October, 2022

**EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union**

19 October, 2022

**90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster**

17 October, 2022

**Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries**

**Nanogen**

*News*  - No new digest announcements identified

**Novartis**

*News*  - No new digest announcements identified

**Novavax**

*Press Releases*

Oct 20, 2022

**Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022**

Oct 19, 2022

*Statement*

**U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults**

Oct 19, 2022

**U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults**

**Pfizer**

*Recent Press Releases*

10.18.2022

**Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022**

- Data demonstrate diversity of vaccine and anti-infective portfolio and cutting-edge scientific approach to battling viral and bacterial infections
- Presentations of interest include a late-breaking abstract with the first full data of the efficacy and safety of Pfizer’s bivalent respiratory syncytial virus (RSVpreF) vaccine candidate in older adults; and new data regarding PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), including its effect on COVID-19-related hospitalizations and other medical visits

**R-Pharm**

https://rpharm-us.com/index.php
Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC Joins Hands with UdeA to Boost Biomedicine R&D in Colombia
2022/10/21
...the two parties agree to enhance the exchange of information and technical know-how related to vaccines and therapeutics to promote scientific studies on immunology and microbiology, develop groups of local young talent, and integrate basic and applied immunology into new vaccines, diagnostics and treatments for infectious diseases, etc...

SK Biosciences
Press Releases
SK bioscience Appoints New Executives towards Global Business Growth
2022.10.21
Seoul, South Korea- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, today announced that Dr. Harry Kleanthous, formerly Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation (BMGF), has joined the Company as Executive Vice President of Vaccine R&D Strategy and External Innovation...

Takeda
Newsroom
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
- TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in the EU-M4all Procedure
- Positive Opinion for TAK-003 Based on 4.5 Years of Safety and Efficacy Data from Pivotal Phase 3 Trial of Over 20,000 Children and Adolescents Across Eight Dengue-Endemic Countries
- Marketing Authorization Expected in Coming Months in Europe Followed by Regulatory Decisions in Latin America and Asia

Valneva
Press Releases
October 10, 2022

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences

Vector State Research Centre of Viralogy and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

* * * * *
* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 3
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 10: E913-1027 Oct 2022
https://journalofethics.ama-assn.org/issue/health-care-waste

Health Care Waste
Most health care generated waste is not hazardous, but it is voluminous. Health care organizations have obligations to manage waste in ways that minimize environmental impact and express their status as good citizens of their global, domestic, and regional communities. Resource-rich countries generate on average more than double the amount of hazardous waste per bed per day than resource-poor countries, and waste processing is concentrated in minoritized communities nearly everywhere. Segregating waste and reducing overall volume are key to curbing primary and secondary emissions that contaminate air and water. Decarbonization and moving the health care sector to net-zero emissions are key expressions of sincerity about motivating health equity.
International Centers of Excellence for Malaria Research (ICEMR): Achievements in the Last Decade

Editorial

International Centers of Excellence for Malaria Research: Achievements of the Collaborative Network during the Past Decade

Malla R. Rao1 and B. Fenton Hall1

[Excerpt]

... Because of the collaborative nature of the network, the ICEMRs have been able to establish joint projects across regions, comparing research findings obtained concomitantly using similar protocols, case definitions, and technologies. As a result, it was possible to conduct comparative studies of cerebral malaria (CM) in Africa and Asia using MRI. Radiologists across continents assessed and classified independently scans of children and adults using standardized approaches. Brain magnetic resonance images and blood profiles from cohorts of pediatric and adult CM cases in India and pediatric cohorts in Malawi identified common correlates of brain swelling—namely, high parasite biomass and increased P. falciparum var transcripts associated with binding to host endothelial protein C receptor.27,28 ICEMR investigators in India also showed that brain swelling was increased in older patients with CM, and further evaluated brain volume using the apparent diffusion coefficient (ADC). Fatal CM was associated with decreased ADC in adults, suggesting cytotoxic edema, whereas in children it was associated with increased ADC, consistent with vasogenic edema. They also found brain swellings had different areas of restricted diffusion in children compared with adults. Although brain swelling was observed in approximately two thirds of children and adults, it resolved upon treatment in both populations, and scanned images of survivors exhibited similarities to the “posterior reversible encephalopathy syndrome.”29

By encouraging and facilitating collaboration among centers, the ICEMR program structure has enabled the centers to develop shared protocols and technologies. The ICEMRs have made efforts to harmonize
outcomes and predictor variable definitions, and—to the extent possible—they have adopted Clinical Data Interchange Standards Consortium (https://www.cdisc.org/standards) standards that enable data sharing and facilitate merging of data sets. ICEMRs have also made their data sets publicly accessible via ClinEpiDB (https://clinepidb.org/) and VEuPathDB (https://veupathdb.org/)—databases that host demographic, clinical, vector, phenotypic, and genomic data. In addition to being data repositories, these resources provide access to data mining and analytical tools, thus providing a computational platform to the scientific community. Public access to these resources allows researchers and policymakers to query data across regions and view or download results immediately, obviating the need to merge data sets or struggle with the definitions of variables and their codes.30,31

What sets the ICEMR program apart from most malaria research programs is not only the broad scientific scope and geographic coverage, but also the extensive collaborations between ICEMRs and local ministries of health, non-governmental organizations, and other stakeholders involved in malaria research and control. Quite often, these interactions have resulted in changes to local control strategies and have spurred further linkages and collaborations among partners. The ICEMR program is also unusual in its inclusion of training of early-stage investigators (ESIs) and building research capacity in endemic-country institutions. Over the years, more than 50 ESIs have received hands-on field experience through the ICEMR network, with many going on to become principal investigators on their own NIH grants. In a recent survey by an external consultant, 81% of current and former ICEMR ESIs indicated they were “very satisfied” with the mentorship provided by the program (internal communication, NIAID). In addition to training, ICEMR collaborations have provided endemic-country institutions with valuable experience in grants administration and multidisciplinary field research methods.

For this Supplement, each ICEMR has provided two articles, the first covering some of their salient research findings and achievements during the past decade, and the second describing their engagement with in-country partners and impact on local malaria control policy. The Supplement provides an overview of the how the ICEMRs’ field research and findings have influenced various stakeholders across the spectrum from fundamental malaria research to malaria control and elimination programs.

Annals of Internal Medicine
October 2022  Volume 175, Issue 10  
http://annals.org/aim/issue

Reviews
Maternal, Infant, and Child Health Outcomes Associated With the Special Supplemental Nutrition Program for Women, Infants, and Children - A Systematic Review
FREE
Maya Venkataramani, MD, MPH, S. Michelle Ogunwole, MD, PhD, Laura E. Caulfield, PhD, ... et al.
Pages:1411–1422

Special Articles
Current Clinical Challenges in the Prevention and Management of COVID-19
FREE
Christine Laine, MD, MPH and Deborah Cotton, MD, MPH
Page:1475
Editorials

Asymptomatic Infection? Another Reason to Consider Monkeypox a Disease of Public Health Concern
Stuart N. Isaacs, MD
Pages:1485–1486

Artificial Intelligence – An International Journal
Volume 311 October 2022
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Reviewed earlier)

BMJ Global Health
September 2022 - Volume 7 - 9
https://gh.bmj.com/content/7/9
[Reviewed earlier]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Reviewed earlier)

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Reviewed earlier)

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Reviewed earlier)

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
Research article
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Limited data are available on the effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines in real-world use—especially against Omicron variants in SARS-CoV-2 infection-naïve population.
Authors: Zhuoying Huang, Shuangfei Xu, Jiechen Liu, Linlin Wu, Jing Qiu, Nan Wang, Jia Ren, Zhi Li, Xiang Guo, Fangfang Tao, Jian Chen, Donglei Lu, Xiaodong Sun and Weibing Wang
Citation: BMC Medicine 2022 20:400
Published on: 20 October 2022

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 22 Oct 2022)
Timing and severity of COVID-19 during pregnancy and risk of preterm birth in the International Registry of Coronavirus Exposure in Pregnancy
Studies of preterm delivery after COVID-19 are often subject to selection bias and do not distinguish between early vs. late infection in pregnancy, nor between spontaneous vs. medically indicated preterm deli...
Authors: Louisa H. Smith, Camille Y. Dollinger, Tyler J. VanderWeele, Diego F. Wyszynski and Sonia Hernández-Díaz
Citation: BMC Pregnancy and Childbirth 2022 22:775
Content type: Research Published on: 18 October 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 22 Oct 2022)
Timing and severity of COVID-19 during pregnancy and risk of preterm birth in the International Registry of Coronavirus Exposure in Pregnancy
Studies of preterm delivery after COVID-19 are often subject to selection bias and do not distinguish between early vs. late infection in pregnancy, nor between spontaneous vs. medically indicated preterm deli...
Authors: Louisa H. Smith, Camille Y. Dollinger, Tyler J. VanderWeele, Diego F. Wyszynski and Sonia Hernández-Díaz
Citation: BMC Pregnancy and Childbirth 2022 22:775
Content type: Research Published on: 18 October 2022

COVID-19 epidemiology and changes in health service utilization in Uganda’s refugee settlements during the first year of the pandemic
The COVID-19 pandemic has been characterized by multiple waves with varying rates of transmission affecting countries at different times and magnitudes. Forced displacement settings were considered particularl...
Authors: Chiara Altare, Natalya Kostandova, Jennifer O’Keeffe, Emmanuel Omwony, Ronald Nyakoojo, Julius Kasozi and Paul B. Spiegel
Citation: BMC Public Health 2022 22:1927
Content type: Research Published on: 17 October 2022
The CRISPR Journal
Volume 5, Issue 5 / October 2022
https://www.liebertpub.com/toc/crispr/5/5

Editorial
Extreme Genome Editing
Rodolphe Barrangou
Published Online: 13 Oct 2022
https://doi.org/10.1089/crispr.2022.29155.editorial

The White House executive order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy, issued last month, highlights the importance of biotechnologies. In the context of CRISPR and genome editing, global competition is fierce, with strong commitments in technology development around the world, especially in agriculture in Asia, as well as regulatory challenges in the European Union.

The urge to deploy genome editing commercially at scale is also a reminder that, beyond human genome editing, many complexities remain to editing various genomes. There are important technical and practical considerations to ponder. The development of the CRISPR effector toolbox has been well chronicled, including here, but its deployment in nonmodel commercial species across phylogenetic groups warrants attention. In an ocean of possibilities, the article depicted on the cover of this issue, from Zhang and colleagues, represents a timely example of efforts in metagenomic mining.

Researchers now have access to a portable CRISPR toolbox enabling flexible editing from a single nucleotide (e.g., a base editor) to large-scale genome manipulation (e.g., removing genomic islands in excess of 100 kb), spanning nearly six orders of magnitude in the size of the edit. This elasticity also applies to the size of the organisms that are being manipulated, from submicroscopic viruses (<10⁻⁷ m) to trees that exceed 10 m in height—that is more than eight orders of magnitude in the size of the edited organism. This obviously correlates with the size of the genomes in play, from tens of kilobases...
to tens of gigabases, respectively (seven orders of magnitude in the size of the genome being manipulated).

Some of these theoretical combinations consequently add up to sobering orders of magnitude, from a single base edit in a 30-kb bacteriophage delivered in a single 1-mL dose to 1 kb inserted in a 30-Gb tree genome scaled up to 100,000 hectares of a commercial forest. The depth of our knowledge of most commercial trees and crops oftentimes pales in comparison with how well we know the genomes of some model phage and bacteria. (This too spans orders of magnitude!)

Editing the World

Once a particular genome has been edited for a particular purpose in a select species, one must contemplate the scale at which the edited genome will be deployed. Small viruses such as CRISPR-engineered phages targeting bacteria for infectious disease may be delivered in a single dose (e.g., 1010 particles in 1 mL) released locally at a site of infection in a single patient. Bacteria used in food fermentations may be scaled up industrially to manufacture dairy products such as cheese and yoghurt (humankind consumes ~1021 CRISPR-enhanced starter cultures annually).

Genome-edited crops are anticipated to be planted in 100 million farms (up to 15% of all farms on the planet) by 2030, accounting for ~2% of our global agricultural production. Applications of genome editing in the realm of forestry will of course take more time, but there are already plans to scale up to hundreds of thousands of hectares of edited forests by 2050. Lifespan elasticity is also in play, from simple organisms that replicate in 20 min in ideal conditions to long-lived trees that will hopefully thrive for hundreds of years.

Straightforward Approach, Complicated Processes

Despite the seemingly simple processes inherent to using CRISPR effectors to edit genomes, each species presents unique difficulties (delivery, efficiency, and specificity) and scale up challenges (across space and time). This is compounded by our relatively primitive understanding of important processes (DNA repair pathways and controlling editing outcomes) and limited toolbox (delivery in many plant species).

Thankfully, some enabling technologies will help mitigate certain challenges, such as the affordability of high-throughput sequencing technologies to deepen our understanding of genotypes (what genes should be targeted), machine learning and artificial intelligence to inform editing strategies (how many and what kind of edits should be designed, with multiplexing typically needed for complex traits), and, as always, delivery modalities (RNA-only payloads, viral discovery, and synthetic biology). Inspired by the pioneers leading CRISPR-based clinical trials, an army of livestock, crop, and tree breeders are already defining the next era of agriculture. Meanwhile, molecular microbiologists are manipulating viromes and microbiomes to shape the environment, with hopes to do so at scale. The White House executive order also tasks regulatory agencies to engage with industrial innovators to ensure we collectively do so responsibly, safely, and transparently to mitigate risks. Time will tell whether technical hurdles or regulatory challenges are the limiting factor, in a globally competitive context where geopolitical considerations are also in play, not to mention fears of climate change and economic uncertainty.

Perspective Free

The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective

Annalisa Lattanzi and Danilo Maddalo
Abstract
In a relatively short time, the pharmaceutical industry has witnessed a rapid integration of the CRISPR technology in multiple areas of research, development, therapy, and diagnostics. A unique feature to this system compared with other technologies is the exceptional versatility in adapting to the broad range of needs across the drug discovery pipeline, such as target identification, cell engineering, and in vivo modeling. As a consequence, the CRISPR toolbox has been evolving to address key questions around preclinical and clinical drug development. In this review, we provide a high-level perspective of how CRISPR has impacted several aspects of the drug discovery workflow and the future ahead for this exciting technology.

Current Genetic Medicine Reports
Volume 10, issue 1, March 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-1
[Reviewed earlier]

Current Opinion in Infectious Diseases
October 2022 - Volume 35 - Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 3 Pages: 123-180 September 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 7, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
The European Journal of Public Health
Volume 32, Issue 5, October 2022
https://academic.oup.com/eurpub/issue/32/5
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (9) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 5   September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5
[New issue; No relevant content identified]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
Article
'The community comes to life': How Social Grants Enable Participation in the Local Economy and Possible Effect on Post-COVID-19 Economic Recovery in Soweto South Africa
Chibuikem Charles Nnaeme
Pages: 493-510
Published online: 26 Jun 2022

Genetics in Medicines
Volume 24, Issue 10  Pages A1-A6, 1993-2210 (October 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/10
[New issue; No relevant content identified]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 22 Oct 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
Global Health: Science and Practice (GHSP)
August 2022 | Volume 10 | Number 4
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 22 Oct 2022]
[No new digest content identified]

Global Public Health
Volume 17, Issue 10 (2022)
http://www.tandfonline.com/toc/rgph20/current
(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 22 Oct 2022]
Review
Assessment of the inclusion of vaccination as an intervention to reduce antimicrobial resistance in AMR national action plans: a global review
Vaccination can reduce antibiotic use by decreasing bacterial and viral infections and vaccines are highlighted in the WHO Global Action Plan on Antimicrobial Resistance (AMR) as an infection prevention measur...
Authors: Lotte van Heuvel, Saverio Caini, Michel L. A. Dückers and John Paget
Citation: Globalization and Health 2022 18:85
Published on: 17 October 2022

Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 4 - October 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]
Assessment of performance for a key indicator of One Health: evidence based on One Health index for zoonoses in Sub-Saharan Africa
Authors: Han-Qing Zhao, Si-Wei Fei, Jing-Xian Yin, Qin Li, Tian-Ge Jiang, Zhao-Yu Guo, Jing-Bo Xue, Le-Fei Han, Xiao-Xi Zhang, Shang Xia, Yi Zhang, Xiao-Kui Guo and Kokouvi Kassegne
Content type: Research Article 22 October 2022

International Health
Volume 14, Issue 5, September 2022
https://academic.oup.com/inthealth/issue/14/5
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 1 (Jun 2022)
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 9, No 10 (2022) October 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/92
[Reviewed earlier]

International Journal of Epidemiology
Volume 51, Issue 5, October 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
October 18, 2022, Vol 328, No. 15, Pages 1483-1570
https://jamanetwork.com/journals/jama/currentissue
Original Investigation
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers
The HEROES-RECOVER Network
free access
This study uses a prospective cohort of essential and frontline workers in 6 US states with SARS-CoV-2 infection to examine associations between 2 or 3 doses of mRNA COVID-19 vaccine and attenuation of symptoms and viral RNA load across SARS-CoV-2 viral lineages.

Research Letter

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose

Jessica P. Ridgway, MD; Samuel Tideman, MS; Thomas French, MS; et al.
free access has active quiz

This study assesses the association between COVID-19 mRNA booster immunization compared with vaccination with the primary mRNA vaccination series alone and odds of hospitalization for COVID-19.

JAMA Pediatrics
October 2022, Vol 176, No. 10, Pages 959-1055
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
October 2022 - Volume 20 - Issue 10
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
October 2022 Volume 71 Issue 4 p381-520
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 75 (2022)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 5, October 2022
[Reviewed earlier]

Journal of Development Economics
Volume 158 September 2022
Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 4, October 2022
http://journals.sagepub.com/toc/jre/current

Journal of Epidemiology & Community Health
September 2022 - Volume 76 - 9
https://jech.bmj.com/content/76/9

Journal of Evidence-Based Medicine
Volume 15, Issue 3 Pages: 181-314 September 2022
https://onlinelibrary.wiley.com/toc/17565391/current

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 3, August 2022
https://muse.jhu.edu/issue/48370
Table of Contents

Journal of Immigrant and Minority Health
Volume 24, issue 5, October 2022
Contents

Journal of Immigrant & Refugee Studies
Volume 20, 2022 Issue 3
https://www.tandfonline.com/toc/wimm20/current
Cost-effectiveness analysis of current non-mandatory hepatitis B vaccination coverage vs expanding coverage among healthcare workers in Ethiopia

Ethiopia is a country with high endemicity in Hepatitis B (HepB) virus infection. However, only 14% of healthcare workers (HCWs) are currently immunized via a non-mandatory strategy in the country. Hence, this...

Authors: Dinksew Tewuhibo, Getahun Asmamaw and Wondim Ayene

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:65

Content type: Research Published on: 17 October 2022
Journal of Public Health Policy
Volume 43, issue 2, June 2022
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
October 2022  Volume 19  Issue 195
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 6, August 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96  Number 18  September 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Oct 22, 2022  Volume 400  Number 10361  p1381-1486
https://www.thelancet.com/journals/lancet/issue/current
The Lancet Commissions
The Lancet Commission on ending stigma and discrimination in mental health
Graham Thornicroft, et al.

The Lancet Child & Adolescent Health
Oct 2022  Volume 6  Number 10  p667-746
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Oct 2022  Volume 4  Number 10  e698-e764
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

**Lancet Global Health**
Oct 2022  Volume 10  Number 1 0e1360-e1533
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

**Lancet Infectious Diseases**
Oct 2022  Volume 22  Number 10  p1399-1512, e279-e309
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

**Lancet Public Health**
Oct 2022  Volume 7  Number 10  e801-e884
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

**Lancet Respiratory Medicine**
Oct 2022  Volume 10  Number 10  p925-1008, e87-e93
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

**Maternal and Child Health Journal**
Volume 26, issue 10, October 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-10
[New issue; No digest content identified]

**Medical Decision Making (MDM)**
Volume 42 Issue 7, October 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]

**The Milbank Quarterly**
_A Multidisciplinary Journal of Population Health and Health Policy_
Volume 100, Issue 3  Pages: 617-961  September 2022
https://onlinelibrary.wiley.com/toc/14680009/current

_Perspective_
**Health Equity and the Dynamism of Structural Racism and Public Policy**
COURTNEE MELTON-FANT
Pages: 628-649
**Racism**

Racism casts a huge shadow on science. People of colour and from other historically marginalized groups have been excluded from the scientific enterprise, research has been used to underpin discriminatory thinking, and research outputs have ignored and further disadvantaged marginalized people. Nature has played its part in creating this divisive legacy. In this special issue — the first in the journal’s 153-year history to be overseen by guest editors — Melissa Nobles, Chad Womack, Ambroise Wonkam and Elizabeth Wathuti present articles that examine some of the ways racism has manifested in science, and the direct and detrimental effects this toxic ideology has had on individuals and their communities. By highlighting these issues, Nature aims to help build a more inclusive future for science, and society, in which people of all colours can thrive.

**Editorial  19 Oct 2022**

**Ending racism is key to better science: a message from Nature’s guest editors**

This special issue is our ‘message in a bottle’ from the troubled ship of science. We urge readers to find it. Open it. Act on its contents.
Melissa Nobles, Chad Womack, Elizabeth Wathuti

**Comment 19 Oct 2022**

**Counter the weaponization of genetics research by extremists**

Geneticists must rethink how they conduct their research and how they communicate results.
Jedidiah Carlson, Brenna M. Henn, Sohini Ramachandran

---

**Nature Biotechnology**
Volume 40 Issue 10, October 2022
https://www.nature.com/nbt/volumes/40/issues/10
[Reviewed earlier]

---

**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 22 Oct 2022)
[No new digest content identified]

---

**Nature Genetics**
Volume 54 Issue 10, October 2022
https://www.nature.com/ng/volumes/54/issues/10
[Reviewed earlier]

---

**Nature Human Behaviour**
Editorial  18 Oct 2022

**Why and how science should respect the dignity and rights of all humans**

In a recent editorial, we announced the adoption of new ethics guidance for research about human groups. In this follow-up editorial, we provide background and examples to clarify why we developed this guidance and how we will be using it.

Article  07 Jul 2022

**Public use and public funding of science**

Studying production, funding and consumption of science, the authors find a strong alignment between what the public consumes and what is impactful, as well as an alignment between funding and collective public use.

Yian Yin, Yuxiao Dong, Benjamin F. Jones

Article  Open Access 11 Jul 2022

**The effects of cash transfer programmes on HIV-related outcomes in 42 countries from 1996 to 2019**

Cash transfers are a popular anti-poverty strategy worldwide. In this study of 42 countries over 24 years, Richterman and Thirumurthy find that large cash transfer programmes were associated with improvements in a variety of HIV-related outcomes.

Aaron Richterman, Harsha Thirumurthy

Article  Open Access 23 Jun 2022

**Combining interventions to reduce the spread of viral misinformation**

Using a mathematical model of viral spread and Twitter data, Bak-Coleman and coauthors show how a combination of interventions, such as fact-checking, nudging and account suspension, can help combat the spread of misinformation.

Joseph B. Bak-Coleman, Ian Kennedy, Jevin D. West

Article  Open Access 11 Jul 2022

**The globalizability of temporal discounting**

Ruggeri et al. find in a study of 61 countries that temporal discounting patterns are globally generalizable. Worse financial environments, greater inequality and high inflation are associated with extreme or inconsistent long-term decisions.

Kai Ruggeri, Amma Panin, Eduardo García-Garzon

Nature Medicine

Volume 28 Issue 10, October 2022

https://www.nature.com/nm/volumes/28/issues/10

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 10, October 2022

https://www.nature.com/nrd/volumes/21/issues/10

[Reviewed earlier]
**Nature Reviews Genetics**
Volume 23 Issue 10, October 2022
https://www.nature.com/nrg/volumes/23/issues/10
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 22 Issue 10, October 2022
https://www.nature.com/nri/volumes/22/issues/10
[Reviewed earlier]

**New England Journal of Medicine**
October 20, 2022  Vol. 387  No. 16
https://www.nejm.org/toc/nejm/medical-journal
*Editorials*
**Audio Interview: Covid-19: Where Are We Heading?**
E.J. Rubin, L.R. Baden, and S. Morrissey

**npj Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 22 Oct 2022]
*Article*  21 Oct 2022
**Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection**
Kayla A. Holder, Danielle P. Ings, Michael D. Grant

**Pediatrics**
Volume 150, Issue 4  October 2022
https://publications.aap.org/pediatrics/issue/150/3
[Reviewed earlier]

**PharmacoEconomics**
Volume 40, issue 10, October 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-10
[New issue; No digest content identified]

**PLoS Biology**
https://journals.plos.org/plosbiology/
(Accessed 22 Oct 2022)
[No new digest content identified]
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Research Article | published 19 Oct 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004120

Shared understandings of vaccine hesitancy: How perceived risk and trust in vaccination frame individuals’ vaccine acceptance
Mauro Martinelli, Giuseppe Alessandro Veltri
Research Article | published 21 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0276519

Influenza vaccination coverage among an urban pediatric asthma population: Implications for population health
Sarah J. Parker, Amy M. DeLaroche, Alex B. Hill, Rajan Arora, Julie Gleason-Comstock
Research Article | published 21 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0269415

Use of traditional and complementary medicine for COVID-19 prophylaxis among healthcare professionals and students in Jordan: A cross-sectional study
Nailya Bulatova, Sara Younes, Majd Arabiyat, Ahmad Abukaff, Sara Madanat, Eman Alqudah, Anoud Hamati, Farah Halawa, Abdallah Younes
Research Article | published 20 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0276015

Acceptance and hesitancy of COVID-19 vaccine among Nepalese population: A cross-sectional study
Determinants of incomplete childhood immunization among children aged 12–23 months in Dabat district, Northwest Ethiopia: Unmatched case-control study
Moges Muluneh Boke, Getaw Tenaw, Neamin M. Berhe, Woynhareg Kassa Tiruneh
Research Article | published 20 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274501

Acceptance and hesitancy of parents to vaccinate children against coronavirus disease 2019 in Saudi Arabia
Ahd Almansour, Sarah M. Hussein, Shatha G. Felemban, Adib W. Mahamid
Research Article | published 18 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0276183

PNAS - Proceedings of the National Academy of Sciences of the United States
October 18, 2022 vol. 119 no. 42
https://www.pnas.org/toc/pnas/119/42
Perspective October 10, 2022Coronavirus (COVID-19)
Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses
COVID-19 is the latest zoonotic RNA virus epidemic of concern. Learning how it began and spread will help to determine how to reduce the risk of future events. We review major RNA virus outbreaks since 1967 to identify common features and opportunities to ... Gerald T. Keusch, John H. Amuasi,[...] Linda Saif

Prehospital & Disaster Medicine
Volume 37 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 163 October 2022
[New issue; No digest content identified]
Proceedings of the Royal Society B
26 October 2022 Volume 289 Issue 1985
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 211 Pages 1-170 (October 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 5, September/October 2022
https://journals.sagepub.com/toc/phrg/137/5
Case Study
Open Access Research article First published 6 June, 2022 pp. 820–825
Partnership Between a Federal Agency and 4 Tribal Nations to Improve COVID-19 Response Capacities
Harpriya Kaur PhD, MPH, Seh Welch PhD, Ravikiran Bhairavabhotla PhD [...]

Restricted access Research article First published 21 July, 2022 pp. 832–840
Implementing the COVID-19 Rapid Community Assessment on Vaccine Confidence: Lessons Learned From Alabama and Georgia
Rosemarie Kobau MPH, Monique Carry PhD, Beth L. Rubenstein PhD, Damian Denson PhD [...] View all

Restricted access Research article First published 12 July, 2021 pp. 867–877
Missed Opportunities for Human Papillomavirus Vaccination by Parental Nativity, Minnesota, 2015-2018
Emily A. Groene MA, Keith J. Horvath PhD, Nicholas Yared MD, Inari Mohammed MPH [...] View all

Qualitative Health Research
Volume 32 Issue 12, October 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 18 Issue 4, October 2022
http://journals.sagepub.com/toc/reab/current
Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 22 Oct 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 9  Pages: 1893-2124  September 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Series: Systemic Risks
Introduction to Special Series
Pia-Johanna Schweizer, Ortwin Renn
Pages: 1900-1901
First Published: 17 October 2022

Systemic Risks from Different Perspectives
Ortwin Renn, Manfred Laubichler, Klaus Lucas, Wolfgang Kröger, Jochen Schanze, Roland W. Scholz, Pia-Johanna Schweizer
Pages: 1902-1920
First Published: 16 December 2020

Systemic Risk: The Threat to Societal Diversity and Coherence
Ortwin Renn, Klaus Lucas
Pages: 1921-1934
First Published: 21 January 2021

Theory of Systemic Risks: Insights from Physics and Chemistry
Klaus Lucas
Pages: 1935-1944
First Published: 13 July 2020

A Proposal for Integrating Theories of Complexity for Better Understanding Global Systemic Risks
Armin Haas, Manfred Laubichler, Joffa Applegate, Gesine Steudle, Carlo C. Jaeger
Pages: 1945-1951
First Published: 03 November 2020
When the advocacy group America’s Frontline Doctors appeared on the steps of the United States Supreme Court in 2020, falsely stating that hydroxychloroquine was a cure for COVID-19, their pronouncement was virally shared by right-wing media and soundly debunked by medical academicians. A year later, one of these frontliners, Joseph Ladapo, became the surgeon general of Florida and a faculty member at the University of Florida College of Medicine. He has continued to spread dangerous misinformation about COVID-19 while his academic colleagues are shamefully silent.

Many assumed that Ladapo’s faculty appointment was the result of political pressure by the university’s administration as it aimed to please Florida Governor Ron DeSantis. It was unsurprising that anti-vax DeSantis wanted a surgeon general with antiscience views. But it was shocking that the medical school accepted Ladapo as a colleague. Even more shocking was a statement from the university president in the Tampa Bay Times confirming that Ladapo was voted into his position by the faculty and approved through the usual procedures. Even Ladapo’s former supervisor at the University of California, Los Angeles, considered his approach to COVID-19 so dangerous as to violate the Hippocratic oath to do no harm, and declined to endorse him as the state surgeon general.

In his own defense, Ladapo told Politico that he was disappointed with the criticism because good science requires respect for all perspectives. “It’s OK to disagree, and I’ve had no problem with disagreement,” he said, “but what has been really disappointing is how disagreement has become a ticket or a passport to activate personal attacks.” No one would disagree that personal attacks are out of bounds, but his depiction of science is off the mark. Unequal perspectives do not deserve equal time, and challenging scientific consensus requires evidence that has been subjected to peer review and published with all the data disclosed so that the scientific community can replicate the findings.

Ladapo recently has been circulating an unattributed study apparently showing that the risk of heart complications from mRNA vaccines to COVID-19 makes them harmful for males under 40. To be taken seriously, such a major challenge to scientific consensus requires rigorous review and wide evaluation of the underlying data. Nothing like that happened. “Ladapo’s dissemination of flawed data that purports a risk of cardiac death among men age 18 to 39 after mRNA vaccines was baseless, reckless, and irresponsible,” said cardiologist Eric Topol. “The risk of myocarditis in this demographic is real and notable, but all studies with close follow-up have indicated it is typically mild and fully resolves in nearly all affected.”

Ladapo has tried to initiate a scientific “debate” on Twitter about the study, saying “I love the discussion that we’ve stimulated.” This move is from page 1 of the antiscience playbook. A credentialed scientist from outside the field questions scientific consensus in a public manner that undermines trust.
in science. Many have played this role during the pandemic, but the pattern reaches back decades to scientists who have, for political purposes, challenged consensus on tobacco, ozone, strategic defense, and climate change.

This raises the question of what responsibility the scientific community has to condemn its members when they enable the spread of misinformation. The situation at the University of Florida creates an opportunity to wrestle with this issue. Ladapo has confirmed his doubters’ fears and has betrayed the responsibilities afforded by academic freedom and tenure. So far, the university doesn’t seem to want to wrestle with the situation. When I asked for a comment, the university health system did not specifically address the Ladapo affair but said in a statement that they continued to support recommendations from the Centers for Disease Control and Prevention on vaccination and that “peer-reviewed publications and data analyses are the gold standard in ensuring accurate conclusions are drawn from the research questions scientists are asking.” That’s far from an adequate response.

It’s easy to blame the politicians, right-wing cable TV hosts, and podcast hucksters for spreading misinformation. But is it defensible to blame these folks without also acknowledging that unchallenged members of the scientific community are making it possible for them to sow this doubt? Until the scientific community deals with misinformation from within, it cannot expect to deal with it from without.

Policy Forum

Science, misinformation, and the role of education
BY Jonathan Osborne, Daniel Pimentel, 20 Oct 2022: 246-248

“Competent outsiders” must be able to evaluate the credibility of science-based arguments

Abstract
Because of the limits to our knowledge and time, we all depend on the expertise of others. For example, most readers of Science accept the anthropogenic origin of climate change. Yet far fewer have actually read a report of the Intergovernmental Panel on Climate Change (IPCC), let alone evaluated the evidence and arguments. Nevertheless, we trust its claims because we rely on the credibility of its authors, the social practices of peer review used to vet any theoretical biases and errors, and the fact that it represents a consensus report of the relevant experts. Alternatively, we can choose to trust the media that report its findings. Amid increasing concern about trust in science being undermined by an ocean of misinformation (1–3), we consider how scientists, science curricula, and science educators must help equip individuals to evaluate the credibility of scientific information, even if the science is beyond their understanding (4).

Science and Engineering Ethics
Volume 28, issue 5, October 2022
[Reviewed earlier]

Science Translational Medicine
Volume 14| Issue 667| 19 Oct 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats
Kristine A. Moore, Michael T. Osterholm, Eve M. Lackritz, Gregory A. Poland
Pages 6001-6003

Country immunization policies for refugees across 20 low-middle income and 20 high-income countries
Jad A. Elharake, Saad B. Omer, Jason L. Schwartz
Pages 6017-6022

Highlights
- 13/20 LMICs and 14/20 HICs included refugees in their national routine immunization policies.
- Refugees should be included in national routine immunization policies.
Refugees should be provided with accessible and affordable immunizations.
Efforts would reduce vaccine-preventable diseases and protect the health of refugee populations—especially during the COVID-19 pandemic.

**Abstract**

In 2020, 26 million refugees resettled in a new country—fleeing their homes due to conflict and persecution. Due to low immunization coverage and underlying health conditions, refugees commonly face an increased risk of contracting vaccine-preventable diseases. We collected and analyzed existing routine immunization policies for refugees across 20 low- and middle-income countries (LMICs) and 20 high-income countries (HICs), each with the highest number of refugees per 1000 residents. Primary and secondary data sources were used to collect policy evidence. Across 20 LMICs, 13 countries specified standing nationwide routine immunization policies for refugees, while 14 out of the 20 HICs included refugees in their national routine immunization programs. LMICs and HICs should include refugees in their national routine immunization policies and provide accessible and affordable immunizations. Such efforts would reduce vaccine-preventable diseases and protect the health of refugee populations—especially during the COVID-19 pandemic.

**Review article  Full text access**

**The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis**
D. Zaçë, E. La Gatta, L. Petrella, M.L. Di Pietro
Pages 6023-6034

**Research article  Full text access**

**Strengthened belief in vaccine effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021**
Ava Kikut, Danielle Clark, Emma Jesch, Robert Hornik
Pages 6035-6041

**Research article  Open access**

**Equity of the Meningitis B vaccination programme in England, 2016–2018**
Karen S. Tiley, Joanne M. White, Nick Andrews, Elise Tessier, Michael Edelstein
Pages 6125-6132

**Value in Health**
October 2022  Volume 25  Issue 10  p1663-1804
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

:::...
:::...

**Pre-Print Servers**

**Gates Open Research**
https://gatesopenresearch.org/browse/articles
Selected Research
No new digest content identified.
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Selected Research

**Global prediction for monkeypox epidemic**
Li Zhang, Jianping Huang, Bin Chen, Yingjie Zhao, Danfen Wang, Wei Yan
medRxiv 2022.10.21.22280978; doi: https://doi.org/10.1101/2022.10.21.22280978

**Investigating inequalities in HIV testing in sub-Saharan Africa: insights from a spatial analysis of 25 countries**
Pearl Anne Ante-Testard, Gabriel Carrasco-Escobar, Tarik Benmarhnia, Laura Temime, Kevin Jean
medRxiv 2022.10.20.22281320; doi: https://doi.org/10.1101/2022.10.20.22281320

**Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021**
medRxiv 2022.10.20.22281327; doi: https://doi.org/10.1101/2022.10.20.22281327

**Uptake of COVID-19 vaccines among healthcare workers within primary healthcare facilities, Entebbe municipality Uganda**
Nassim Kyakwuwa, Christine Atuhairwe, Hamza Kalutte, Simon Mpooya, Flavia Nakanjako, Laurent Perez, Bernard Kikaire
medRxiv 2022.10.20.22281300; doi: https://doi.org/10.1101/2022.10.20.22281300

**Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden**
Peter Nordström, Marcel Ballin, Anna Nordström
medRxiv 2022.10.19.22281286; doi: https://doi.org/10.1101/2022.10.19.22281286
Monkeypox outbreak in the Netherlands in 2022: public health response, epidemiological and clinical characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine
medRxiv 2022.10.20.22281284; doi: https://doi.org/10.1101/2022.10.20.22281284

Parental Preferences and Reasons for COVID-19 Vaccination Among Their Children
Neil Sehgal, Benjamin Rader, Autumn Gertz, Christina M. Astley, John S Brownstein
medRxiv 2022.10.20.22281313; doi: https://doi.org/10.1101/2022.10.20.22281313

Did Risk-based or Age-based Vaccine Prioritization for Covid-19 Save More Lives?
Joeri Smits, Amyn Abdul Malik, Jad A Elharake, Ahmed Mushiq Mobarak, Saad B. Omer
medRxiv 2022.10.18.22281237; doi: https://doi.org/10.1101/2022.10.18.22281237

Impact of a vaccine passport on first-dose COVID-19 vaccine coverage by age and area-level social determinants in the Canadian provinces of Québec and Ontario: an interrupted time series analysis
Jorge Luis Flores Anato, Huiting Ma, Mackenzie A. Hamilton, Yiqing Xia, Sam Harper, David Buckeridge, Marc Brisson, Michael P. Hillmer, Kamil Malikov, Aidin Kerem, Reed Beall, Stefan Baral, Ève Dubé, Sharmistha Mishra, Mathieu Maheu-Giroux
medRxiv 2022.10.18.22281192; doi: https://doi.org/10.1101/2022.10.18.22281192

A systematic review on outbreaks of COVID-19 among children within households in the European region
Constantine I. Vardavas, Katerina Nikitara, Katerina Aslanoglou, Apostolos Kamekis, Nithya Ramesh, Emmanouil Symvoulakis, Israel Agaku, Revati Phalkey, Jo Leonardi-Bee, Esteve Fernandez, Orla Condell, Favelle Lamb, Charlotte Deogan, Jonathan E. Suk
medRxiv 2022.10.17.22281168; doi: https://doi.org/10.1101/2022.10.17.22281168

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 22 Oct 2022]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
Covid-19 Spillover Effects onto General Vaccine Attitudes
Kristin Lunz Trujillo
Jon Green
Alauna Safarpour
David Lazer
Jennifer Lin
Matthew Motta
Last edited: Oct 20, 2022 UTC
Even amid the unprecedented public health challenges attributable to the COVID-19 pandemic, opposition to vaccinating against the novel coronavirus has been both prevalent and politically contentious in American public life. In this paper, we theorize that attitudes toward COVID-19 vaccination might ...

**Wellcome Open Research**  [to 22 Oct 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 22 Oct 2022]
*Selected Research*
No new digest content identified

---

**Think Tanks**

**Brookings**  [to 22 Oct 2022]
http://www.brookings.edu/
*Latest Research [Selected]*
No new digest content identified

**Center for Global Development**  [to 22 Oct 2022]
https://www.cgdev.org/
*All Research [Selected]*
WORKING PAPERS
*Exploring the Effects of the COVID-19 Pandemic on Low-Cost Private Schools in Nairobi, Kenya*
Olivier Habimana et al.
October 19, 2022
To contain the spread of the COVID-19 pandemic, schools in Kenya, as in many other countries, had to temporarily close. This study investigates the extent to which lockdowns and school closures affected households and low-cost private schools (LCPS) in four urban informal settlements in Nairobi. Qua...

**CGD NOTES**
*WASHing Away Resistance: Why the UK Should Invest in Water, Sanitation, and Hygiene to Tackle Anti-Microbial Resistance*
Anthony McDonnell and Katherine Klemperer
October 19, 2022
This note was first published as evidence submitted to the joint inquiry of the UK All-Party Parliamentary Groups (APPGs) on WASH and Antibiotics into the links between antibiotic resistance and lack of access to WASH.
**Chatham House**  [to 22 Oct 2022]
https://www.chathamhouse.org/
Selected Analysis, Comment
No new digest content identified

**CSIS**  [to 22 Oct 2022]
https://www.csis.org/
Selected Reports Report
**The Ending the HIV Epidemic in the U.S. Initiative: An Interim Assessment and Policy Recommendations**
October 21, 2022 | Jeffrey Sturchio, Mackenzie Burke, Maclane Speer  Midway through the first phase of Ending the HIV Epidemic in the U.S., the program is off track from its goal of reducing new HIV infections to 9,250 people or fewer by 2025. This moment presents an opportunity to evaluate the initiative and address the challenges ahead.

**Kaiser Family Foundation**  [to 22 Oct 2022]
https://www.kff.org/search/?post_type=press-release
Press Releases
October 18, 2022  *News Release*
**With Government Funding Running Out, Americans Could Soon Face New Challenges in Accessing COVID-19 Treatments and Testing**
A new KFF brief analyzes how the accessibility and cost of COVID-19 vaccines, treatments, and tests will change after the current government supply is depleted and the public health emergency ends. The Biden Administration has announced that it will have to end its purchase and distribution of COVID supplies as...

**ODI [Overseas Development Institute]**  [to 22 Oct 2022]
Publications
No new digest content identified.

**Pew Research Center**  [to 22 Oct 2022]
https://www.pewresearch.org/
Latest Publications
No new digest content identified.

**Rand**  [to 22 Oct 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Brochure
**Disaster Management and Resilience**
This brochure describes RAND’s work, which directly supports decisionmakers in developing actionable planning and policy for disaster management and resilience.
Oct 20, 2022

Report
Policy Decisionmaking in Long-Term Care: Lessons from Infection Control During the COVID-19 Pandemic
   Policies to prevent the spread of COVID-19 in long-term care facilities have failed to balance community safety and resident well-being. Input from a range of stakeholders highlighted a need for inclusive policy decisionmaking in long-term care.
Oct 20, 2022
Lori Frank, Thomas W. Concannon, Jordan M. Harrison, Sarah Zelazny

Urban Institute  [to22 Oct 2022]
https://www.urban.org/publications
New Research Publications

World Economic Forum  [to22 Oct 2022]
Media
Gene Therapy Access Can Significantly Reduce Global Disease Burden
News 18 Oct 2022
   - Gene therapy can help millions of people globally if applied appropriately across all markets
   - However, the complexity and record-breaking prices of these new medical innovations severely limits access for those most in need
   - New World Economic Forum paper outlines path to ensuring that countries and communities with high burdens of disease are not left behind
   - Explore the full report, figures and more information here

*   *   *   *   *
*   *   *   *   *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

* This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation,
Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*     *     *     *     *
*     *     *     *     *